SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
Status:
Recruiting
Trial end date:
2021-03-28
Target enrollment:
Participant gender:
Summary
Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma
are recruited to this prospective non-randomized study comprising two separate cohorts.
Patients will receive SHR-1210, a novel anti-PD-1 antibody, with apatinib and either
irinotecan or paclitaxel liposome plus nedaplatin. The primary endpoint is to determine the
objective response rate (ORR) of patients in both cohorts. The regimen(s) of promising
efficacy will be further verified in subsequent randomized studies to define the optimal
combination of immunotherapy, anti-angiogenesis and chemotherapy in advanced esophageal
cancer patients.